最新刊期

    34 21 2023
    • YANG Liu,HAN Yong,SHEN Qing,ZHOU Yimeng,REN Wei,YAN Junfeng,TONG Rongsheng
      Vol. 34, Issue 21, Pages: 2561-2577(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.01
      摘要:In order to standardize the review and comment of national key monitoring drug prescriptions (medical orders) by medical institutions at all levels, the Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital took the lead in compiling the Review and Comment Rules of National Key Monitoring Drugs prescriptions (Medical Orders) herein after referred to as the Rules in accordance with the Second Batch of National Key Monitoring Rational Drug Use List (hereinafter referred to as the List) issued by the National Health Commission confirmed in Jan. 13, 2023. According to the laws and drug instructions issued by the national drug regulatory department, clinical guidelines and expert consensus, combined with the actual situation of patients (including age, body weight, liver and kidney function), the writing group classified the common and unreasonable drug use problems for 30 kinds of drugs included in the List and develop the review and comment details. After two rounds of Delphi method questionnaire research and experts’ online meetings, and reviewed by the steering committee, the final Rules was formed. The Rules aim to provide reference for the evaluation of the rational use of drugs included in the List by medical institutions, so as to realize the standardized management of key monitoring drugs, promote the rational drug use in medical institutions, and ensure the safety of drug use for patients.  
      关键词:rational drug use;review and comment rules;medical institutions   
      99
      |
      37
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809665 false
      发布时间:2023-11-10
    • WANG Huiling,YUE Zhongsheng,QIAN Yating,CAO Linlin,XIAO Haoxiang,LIU Wei
      Vol. 34, Issue 21, Pages: 2578-2582(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.02
      摘要:OBJECTIVETo analyze the patterns and characteristics of drug-related administrative penalty cases with medical institutions as parties from 2020 to 2022 in order to further improve drug management in medical institutions.METHODSA retrospective statistical analysis was used to summarize the drug-related administrative penalty decisions with medical institutions as parties, and to match them with the provisions of the Drug Administration Law (2019 version) for statistical analysis.RESULTSThere were 144 complete administrative penalty decisions with medical institutions as parties. Analyzed by cause, 126 cases of administrative punishment for inferior drugs accounted for 87.50%, of which expired drugs accounted for more than 50.00% of the inferior drug cases; 15 cases (10.42%) were for purchasing drugs from enterprises or individuals not qualified to operate drugs. Analyzed by the range of punishment amount of the cases, 34 cases (23.61%) resulted in lighter penalties, while 81 cases (56.25%) resulted in reduced penalties.CONCLUSIONSThere are extremely few medical institutions that have received administrative penalties for drug management violations. Medical institutions should strengthen the awareness of law-abiding, and know the red line of drug management and the illegal behavior that is easy to occur, so as to better strengthen drug quality management.  
      关键词:drug;medical institutions;inferior drugs   
      59
      |
      6
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809664 false
      发布时间:2023-11-10
    • JIANG Ying,JIANG Rong
      Vol. 34, Issue 21, Pages: 2583-2588(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.03
      摘要:OBJECTIVETo provide feasible regulatory paths for the online sales supervision of Chinese medicinal materials from the perspective of the characteristics of new online sales and the characteristics of Chinese medicinal materials.METHODSThrough the investigation of the sales form of Chinese medicinal materials on the e-commerce platform and the search of Chinese medicinal materials online dispute cases, the difficulties and existing problems in the supervision of Chinese medicinal materials under the new online sales model were analyzed, and corresponding countermeasures were proposed. RESULTS &CONCLUSIONSClarifying the conceptual boundary between Chinese medicinal materials and their decoction pieces, agricultural products and food is the key to standardizing the online sale of Chinese medicinal materials. The regulatory criteria, which determine whether Chinese medicinal materials belong to drug management based on whether they had been included in medicinal channels, didn’t consider the diversity of online sales channels for Chinese medicinal materials, their safety and the disguised sales of Chinese herbal decoction pieces. It is necessary to establish the concept of hierarchical management of Chinese medicinal materials, strictly restrict the behavior of claiming the efficacy of Chinese medicinal materials and selling Chinese herbal decoction pieces in live streaming, improve the defining path of false propaganda of Chinese medicinal materials, implement the responsibilities and obligations of live streaming marketing subjects and platforms, and safeguard the legitimate rights of consumers.  
      关键词:network supervision;live streaming;false propaganda;subject responsibility   
      52
      |
      4
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809891 false
      发布时间:2023-11-10
    • FU Jia,ZHOU Sainan
      Vol. 34, Issue 21, Pages: 2589-2594(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.04
      摘要:OBJECTIVETo explore the improvement effect and mechanism of Simotang oral liquid on functional dyspepsia (FD) model rats by regulating PTEN-induced putative kinase 1 (Pink1)/E3 ubiquitin ligase (Parkin) axis.METHODSSD male rats were subjected to unpredictable chronic stress to establish an FD model, and were randomly grouped into the model group, positive control group (Domperidone tablets, 3.5 mg/kg), Simo decoction group (Simotang oral liquid, 5.4 mL/kg), with 20 rats in each group. The blank group without modeling was set up. Administration groups were given relevant medicine intragastrically, blank group and model group were given constant volume of normal saline intragastrically, once a day, for consecutive 14 d. After the last administration, the gastric emptying rate and small intestine propulsion rate of rats were detected. The contents of gastrointestinal hormones [motilin (MTL), gastrin (GAS) and cholecystokinin (CCK)] in rats were determined; the mitochondrial structure of ICC in gastric antrum tissue of rats was observed; the immunofluorescence co-localization method was applied to observe the expression of cytochrome C oxidase Ⅳ (COX Ⅳ) and Parkin in gastric antrum tissue of rats; the protein expressions of LC3, p62, Pink1 and Parkin in gastric antrum tissue of rats were all detected.RESULTSCompared with the blank group, the gastric emptying rate, small intestinal propulsion rate, the serum contents of MTL and GAS, and protein expression of p62 in model group were all reduced significantly (P<0.05); the serum content of CCK, the co-localization expression of COX Ⅳ and Parkin in mitochondria, the protein expressions of LC3, Pink1 and Parkin were all increased significantly (P<0.05). The number of ICC mitochondria in gastric antrum tissue decreased, mitochondria became vacuolated, mitochondrial cristae were blurry, and there were more autophagic lysosomes. Compared with the model group, the above indexes of the positive control group and the Simo decoction group were reversed significantly (P<0.05); the mitochondrial structure of ICC gradually recovered, with clear mitochondrial cristae and reduced autophagic lysosomes.CONCLUSIONSSimotang oral liquid can improve gastrointestinal motility and gastrointestinal hormone levels in FD model rats, the mechanism of which may be related to inhibiting Pink1/Parkin axis and blocking autophagy.  
      关键词:PTEN-induced putative kinase 1;E3 ubiquitin ligase;functional dyspepsia;autophagy   
      21
      |
      8
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809777 false
      发布时间:2023-11-10
    • CHEN Xueyan,WEI Wenzhi,ZHANG Minjuan,ZHANG Yaoyuan,A Yumei,PENG Shuang
      Vol. 34, Issue 21, Pages: 2595-2600(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.05
      摘要:OBJECTIVETo establish a method for the simultaneous determination of 10 rhubarb anthraquinones in Compound gentian sodium bicarbonate tablets and the content of rhaponticin,which are the characteristic components of artifacts,and to use the method to evaluate the quality of compound preparation containing Rheum officinale.METHODSThe ultra-performance liquid chromatography (UPLC) method was adopted to determine the contents of 10 rhubarb anthraquinones (aloe-emodin-8-O-glucoside,rheinic acid-8-O-β-D-glucoside,emodin-8-O-glucoside,chrysophanol-8-O-β-D-glucoside,emodin monomethyl ether-8-O-β-D-glucoside,aloe-emodin,rheinic acid,emodin,chrysophanol,emodin monomethyl ether) and rhaponticin in 40 batches of Compound gentian sodium bicarbonate tablets from 8 manufacturers. The determination was performed on the Agilent Eclipse Plus C18 column with a mobile phase consisted of acetonitrile-0.1% phosphoric acid solution (gradient elution) at a flow rate of 0.3 mL/min; the column temperature was set at 30 ℃,and the injection volume was 5 μL. Combining principal component analysis and cluster analysis to synthesize the results of content determination,the quality of samples from different manufacturers was evaluated.RESULTSAll of above 11 components showed favorable linear relationships with peak areas in their respective mass concentration ranges (r≥0.999 3),with RSDs of precision,repeatability and stability less than 3% (n=6); average sample recoveries ranged 96.82%-98.92% (RSD≤1.74%,n=6); their contents were 0.011 7-0.252 0,0-0.323 3,0.131 3-1.236 6,0.081 1-1.056 2,0.015 2-0.189 8,0.001 8-0.152 3,0-0.255 2,0.001 9-0.223 4,0.054 3-0.303 0,0.022 7-0.172 2,0-2.835 9 mg/g,respectively. The cumulative variance contribution of the first three principal components was 95.533%; the 40 batches of samples can be clustered into 4 categories:samples from enterprises a and d were in a category of their own,samples from enterprises f,b,g and e were in a category,and samples from enterprises c and h were in a category. There were large differences in the content of rhubarb anthraquinone in the samples from 8 manufacturers,and rhaponticin was only detected in the sample from one enterprise.CONCLUSIONSEstablished UPLC method is stable and reliable; it can be used for the content determination of 10 rhubarb anthraquinones and rhaponticin in Compound gentian sodium bicarbonate tablets.  
      关键词:rhaponticin;rhubarb anthraquinones;ultra-performance liquid chromatography   
      37
      |
      4
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43810084 false
      发布时间:2023-11-10
    • ZHENG Wei,LANG Jing,HUANG Xifeng,XIAO Rui,BAI He,JIA Ji
      Vol. 34, Issue 21, Pages: 2601-2607(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.06
      摘要:OBJECTIVETo observe the effects of chlorogenic acid on the activation of macrophage induced by lipopolysaccharide (LPS), and to explore the role of triggering receptors expressed on myeloid cells-2 (TREM2) in the action.METHODSTo find a suitable LPS concentration, the cells were cultured with 1, 10 and 100 ng/mL LPS for 24 h. The level of interleukin 6 (IL-6) in the cell culture supernatant and protein expression of inducible nitric oxide synthase (iNOS) in the cells were detected. To search for a suitable chlorogenic acid concentration, the cells were divided into control group, LPS group and three chlorogenic acid (0.01, 0.1 and 1 μmol/L)+LPS groups. The levels of tumor necrosis factor α (TNF-α) and IL-1β in the cell culture supernatant, the protein expressions of iNOS and TREM2 in the cells and cell viability were detected. To observe the effects of TREM2 in chlorogenic acid alleviating macrophage activation, TREM2-small interfering RNA (TREM2-siRNA) was taken to intervene in TREM2 protein expression. The cells were divided into control group, LPS group, chlorogenic acid+LPS group, TREM2-siRNA+chlorogenic acid+LPS group and SC-siRNA+chlorogenic acid+LPS group. After 24 h incubation, the levels of TNF-α and IL-1β in the cell culture supernatant and protein expressions of TREM2, iNOS and nuclear factor κB p65 (NF-κB p65) in the cells were detected.RESULTS10 ng/mL LPS promoted IL-6 release and increased iNOS protein expression, and 10 ng/mL LPS was taken in the next experiments. Compared with the LPS group, 0.1 μmol/L chlorogenic acid decreased TNF-α and IL-1β levels, and down-regulated iNOS expression, meanwhile increased TREM2 expression without effect on cell viability, and 0.1 μmol/L chlorogenic acid was taken in the next experiments. Compared with the control group, the protein expressions of iNOS and NF-κB p65 in the LPS group were significantly increased (P<0.05); compared with the LPS group, the protein expressions of iNOS and NF-κB p65 in the chlorogenic acid+LPS group were significantly decreased, the protein expressions of TREM2 was significantly increased (P<0.05); compared with the chlorogenic acid+LPS group, the protein expressions of iNOS and NF-κB p65 of TREM2-siRNA+chlorogenic acid+LPS group were significantly increased, the protein expressions of TREM2 was significantly decreased (P<0.05). TREM2-siRNA could significantly reverse the above effects of chlorogenic acid, while SC-siRNA did not significantly affect the above anti-inflammatory effects of chlorogenic acid.CONCLUSIONSChlorogenic acid can inhibit the LPS-induced macrophage activation, and its anti-inflammatory may be mediated by TREM2 protein.  
      关键词:macrophage;lipopolysaccharide;inflammation;triggering receptors expressed on myeloid cells-2   
      21
      |
      5
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809993 false
      发布时间:2023-11-10
    • MAO Xiaowen,GU Zhirong,WANG Yuanyuan,GE Bin
      Vol. 34, Issue 21, Pages: 2608-2612(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.07
      摘要:OBJECTIVETo optimize the molding process of Shuangye pipa granules based on the concept of quality by design (QbD) and analyze its physical fingerprint.METHODSThe dry extract of Shuangye pipa granules was used as the main drug. The retention rate of total flavonoid, moisture absorption rate, dissolution rate, angle of repose and molding rate of the granules were selected as evaluation indexes. The single-factor test combined with the entropy weight method and Box-Behnken response surface design was used to optimize the molding process, and validation test was conducted. The physical fingerprints of 10 batches of Shuangye pipa granules prepared by the optimal process were comprehensively analyzed by eight secondary physical indexes (relative homogeneity, moisture, moisture absorption rate, Hausner ratio, angle of repose, bulk density, tap density and porosity).RESULTSThe optimal molding process of Shuangye pipa granules was as follows: soluble starch-maltodextrin-mannitol was 1∶1∶1 (m/m/m), 95% ethanol was as wetting agent and the amount of it was 37%, the drug-assisted ratio was 1∶0.8 (m/m), the drying temperature was 59 ℃, drying time was 28 min. The results of 3 validation tests showed that the average comprehensive score was 0.879 6, the RSD of which with prediction value (0.881 9 score) was 1.97%. The similarity between the physical fingerprints of 10 batches of Shuangye pipa granules and the control physical fingerprint was higher than 0.99.CONCLUSIONSThe optimized molding process of Shuangye pipa granules is stable and feasible, and the physical property of Shuangye pipa granules is stable and controllable.  
      关键词:molding process;Box-Behnken response surface design;entropy weight method;physical fingerprint;quality by design   
      12
      |
      2
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809775 false
      发布时间:2023-11-10
    • FAN Zhixin,LIU Junyang,ZHANG Liwei,SI Xu,HE Qing,SUN Qiang,YIN Jia
      Vol. 34, Issue 21, Pages: 2613-2619(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.08
      摘要:OBJECTIVETo analyze existing problems of pharmacoeconomic evaluation research in China and to improve the standardization and scientificity of research, so as to provide more high-quality evidence for government decision-making.METHODSRetrieved from CNKI, Wanfang database, VIP, PubMed, Web of Science from 2018 to 2022, the literature related to pharmacoeconomic evaluation in China was collected; Excel 2016 software was used to extract the key information of the included literature which met inclusion criteria. The Quality of Health Economic Studies (QHES) scale was used to evaluate the quality of the included literature.RESULTSA total of 113 pieces of literature were included in this study, involving 85 pieces of Chinese literature and 28 pieces of English literature. The overall score of QHES included literature was 65.7, of which the average score of Chinese literature was 62.0 and English literature was 76.9. The median quality scores for the literature in 2018, 2019, 2020, 2021 and 2022 were 62.0, 70.5, 59.3, 71.0, and 73.0, respectively. Of these, 65 pieces of literature reported the research perspective; 36 reported the discount rate indistinctly; 25 provided unclear definitions of thresholds; and 53 used two sensitivity analysis methods. Among different items of the QHES scale, item 2 (research perspective), item 8 (time range and discount rate), item 14 (potential bias) and item 16 (sources of funding) had low percentage of scores.CONCLUSIONSFrom 2018 to 2022, pharmacoeconomic evaluation literature published by Chinese academics has generally shown a fluctuating upward trend in terms of quality, but there is still some room for improvement. The main problems in current pharmacoeconomics research in China include unclear understanding of the research perspective, single measurement of cost and health outcomes, unreasonable design of time horizon, indistinct description of the threshold or discount rate, and lack of sensitivity analysis.  
      关键词:quality evaluation;China;Quality of Health Economic Studies scale   
      14
      |
      8
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809987 false
      发布时间:2023-11-10
    • YAN Haiyan,HE Wenming,LI Guoxian,LUO Keyu,QIN Xiangsong,WEI Huifen,ZHANG Peng,JIANG Zhongsheng
      Vol. 34, Issue 21, Pages: 2620-2624(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.09
      摘要:OBJECTIVETo investigate the occurrence time and risk factors of anemia in patients with acquired immune deficiency syndrome (AIDS) after taking highly active antiretroviral therapy (HAART) containing zidovudine.METHODSThe clinical data of 2 150 AIDS patients who were followed up in the care clinic of Liuzhou People’s Hospital from January 1, 2010 to December 31, 2022 were collected. The occurrence time of anemia was analyzed retrospectively, and the risk factors of anemia were analyzed by univariate analysis and binary Logistic regression analysis.RESULTSA total of 854 AIDS patients receiving HAART containing zidovudine were collected, and 107 patients (12.53%) developed anemia. Most of them (63.55%) developed anemia within 3 months after treatment. Baseline hemoglobin [OR=2.944, 95%CI (1.195, 7.501), P=0.019], baseline CD4+ T lymphocyte count [OR=2.472, 95%CI (1.117, 5.469), P=0.026] and baseline human immunodeficiency virus-ribonucleic acid(HIV-RNA) [OR=4.299, 95%CI (1.905, 9.705), P<0.001] was associated with anemia.CONCLUSIONSThe median time of anemia in AIDS patients receiving HAART containing zidovudine is the second month after initiation of treatment. Baseline hemoglobin≤110 g/L, baseline CD4+ T lymphocyte count≤100 /mm3, and baseline HIV-RNA≥100 000 copies/mL are independent risk factors for anemia in these patients.  
      关键词:acquired immune deficiency syndrome;human immunodeficiency virus;highly active antiretroviral therapy;anemia;risk factor   
      12
      |
      6
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809985 false
      发布时间:2023-11-10
    • SU Hui,JIANG Tingting,ZHANG Ni,LI Yanping,CAI Yongqing,PENG Dan,LIU Yao
      Vol. 34, Issue 21, Pages: 2625-2630(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.10
      摘要:OBJECTIVETo provide a reference for safe drug use in clinic.METHODSADE reports related to nilotinib from the first quarter of 2007 to the fourth quarter of 2022 were collected from the US FDA adverse event reporting system database. The reporting odds ratio (ROR) and proportional reporting ratio (PRR) of disproportionality measures were used to mine potential ADE signals,which were compared with drug instruction and related case report, and were screened and analyzed according to the designated medical events (DME) list formulated by the European Medicines Agency.RESULTSTotally 23 332 cases of ADE with nilotinib as the primary suspected drug were reported. A total of 359 positive signals were obtained,involving 24 system organ classes (SOC),mainly concentrated in various examinations,heart organ diseases,vascular and lymphatic diseases,all kinds of nervous system diseases,etc. Among them,ADEs such as vertebral artery stenosis,coronary artery stenosis,arterial disease,liver infection and the second primary malignant tumor were not mentioned in the instructions. Seven DMEs were detected,of which bone marrow failure,pulmonary hypertension and deafness were not mentioned in the drug instruction.CONCLUSIONSThe common ADE signals of nilotinib excavated in this study are consistent with the instructions. In clinical use,special attention should be paid to DME not mentioned in the instructions such as bone marrow failure,pulmonary hypertension and deafness; cardiac function, blood glucose and blood lipid indexes should be monitored closely.  
      关键词:nilotinib;adverse drug event;signal mining;disproportionality measures;designated medical events   
      29
      |
      17
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43810069 false
      发布时间:2023-11-10
    • ZHENG Zihui,PAN Huijie,ZHAO Zinan,HU Xin,JIN Pengfei
      Vol. 34, Issue 21, Pages: 2631-2637(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.11
      摘要:OBJECTIVETo systematically evaluate the hemostatic effect and safety of snake venom hemocoagulase drugs in abdominal surgery, so as to provide evidence-based evidence for clinic.METHODSRetrieved from Embase, Cochrane Library, PubMed, China Biomedical Literature Database, CNKI and Wanfang database, randomized controlled trials (RCTs) about 3 kinds of snake venom hemocoagulase drugs (Hemocoagulase injection, Hemocoagulase Bothrops atrox for injection, Haemocoagulase Agkistrodon for injection) in abdominal surgery were collected from the establishment of the database to Aug. 2023. Screening, quality evaluation, and data extraction were conducted on literature according to the inclusion and exclusion criteria, and Cochrane 5.1 was used for literature quality evaluation. The risk bias diagram and network diagram were drawn by Stata 15.1 software, and the Bayesian network meta-analysis was carried out by using R 3.6.2 software and Markov chain-Monte Carlo method.RESULTSA total of 11 studies were included, involving 1 401 patients, 852 in the study group, and 549 in the control group. In terms of hemostatic effect, Hemocoagulase injection was significantly superior to Haemocoagulase Agkistrodon for injection [MD=-2.45, 95%CI (-4.39,-0.24), P<0.05], and the probability of reducing intraoperative bleeding was ranked as follows: Hemocoagulase injection>hemocoagulase B. atrox for injection>Haemocoagulase Agkistrodon for injection; in terms of safety, there was no statistically significant difference between the three snake venom hemocoagulase drugs and placebo (P>0.05).CONCLUSIONSThe hemostatic effect of Hemocoagulase injection in abdominal surgery is significantly better than that of Haemocoagulase Agkistrodon for injection; all three snake venom hemocoagulase drugs have good safety.  
      关键词:abdominal surgery;hemostatic;effectiveness;safety;Bayesian network meta-analysis   
      21
      |
      7
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809773 false
      发布时间:2023-11-10
    • WU Biao,WANG Jianhua,ZHU Lina,WANG Yubo
      Vol. 34, Issue 21, Pages: 2638-2643(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.12
      摘要:OBJECTIVETo understand the current status of the research on rational drug use among the elderly population in Chinese elderly care facilities, and to provide ideas for future related research.METHODSRetrieved from PubMed, Web of Science, Embase, CNKI, Wanfang database and VIP, relevant literature about the research on rational drug use among the elderly population in Chinese elderly care facilities were collected to evaluate the current status of research on the rational drug use among the elderly population in elderly care facilities.RESULTSA total of 14 cross-sectional studies were included. All included studies were completed before 2019 and focused on the eastern coastal areas of China. The AXIS quality scores of the included studies showed a mean score of 11.14±2.25, with six studies having a quality score >10. The 14 studies examined a total of 5 770 older adults in elderly care facilities, involving 181 elderly care facilities. Eight studies reported the type of chronic disease in the older adult population of the elderly care facilities; seven studies reported the type of medication used. Nine studies had medication compliance as an outcome, among which seven studies used different analytical methods to analyze the factors influencing medication compliance. The results showed that age, education, duration of illness, type of elderly care facilities, and level of staff attention had significant influence on medication compliance in the elderly population in the elderly care facilities.CONCLUSIONSThere is insufficient research related to rational drug use among the elderly population in the elderly care facilities in China, and there is a lack of interventional studies to assess the effectiveness of the rational drug use service in the elderly population in the elderly care facilities. Most of the current research is based on cross-sectional studies, focusing on medication compliance.  
      关键词:elderly care facilities;rational drug use;systematic review   
      27
      |
      10
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809666 false
      发布时间:2023-11-10
    • HANG Yongfu,XU Yan,DAI Xiaohua,WU Tiantian,DUAN Yinyin,XU Deyu,HU Kun,LIU Xingxing,ZHU Jianguo,MIAO Liyan,LI Lin
      Vol. 34, Issue 21, Pages: 2644-2648(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.13
      摘要:OBJECTIVETo develop a whole-process intelligent model of pharmaceutical care for peritoneal dialysis (PD) patients, and to provide a reference for clinical pharmacists to provide standardized PD pharmaceutical care.METHODSThe pharmaceutical care mode of PD patients at home and abroad was investigated and analyzed. Based on the actual situation of the First Affiliated Hospital of Soochow University (hereinafter referred to as “our hospital”), with “home→PD center outpatient→inpatient department” as the main node, the recycling process of medication reconciliation was optimized. The whole-process intelligent pharmaceutical care model of PD was illustrated by improving the Chinese version of the drug-related problems (DRPs) classification tool, developing the corresponding pharmaceutical care process, and presenting specific cases.RESULTSBased on the medication therapy management (MTM) platform, our hospital had built a closed-loop PD whole-process intelligent pharmaceutical care model of “in-hospital pharmaceutical care (building document)-PD outpatient MTM-home pharmaceutical care (online App management)”. A “double cycle” workflow of “admission→discharge→outpatient” medication reconciliation cycle and “discovery-analysis-intervention-follow-up-record-evaluation” DRPs cycle was formed.CONCLUSIONSThe establishment of the whole-process intelligent pharmaceutical care model for PD in our hospital provides experience for standardizing pharmaceutical care for PD patients, and can reduce DRPs.  
      关键词:pharmaceutical care;work model;clinical pharmacist;medication reconciliation;drug-related problems;medication therapy management   
      24
      |
      9
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809781 false
      发布时间:2023-11-10
    • GE Yanhui,CHEN Xiaoli,ZHAO Xiaoyu,CHEN Zhe,GUAN Kelei,DU Shuzhang
      Vol. 34, Issue 21, Pages: 2649-2653(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.14
      摘要:OBJECTIVETo establish the index system of quality evaluation standard for pharmacist training in cough and wheeze pharmaceutical care (CWPC) outpatient department, and to provide a basis for the selection of CWPC pharmacist training teachers and the improvement of training plans.METHODSBased on Kirkpatrick model, using the Delphi method, a total of 15 experts from 13 tertiary hospitals in 10 provinces in China were consulted to establish the standard index system of the quality evaluation for CWPC pharmacists training. Analytic hierarchy process (AHP) was adopted to determine the weights of each indicator and quantify the index system according to the weights of indicators at all levels.RESULTSThe coefficient of expert authority was 0.810, the judgment coefficient was 0.727, and the familiarity coefficient was 0.893. The Kendall coordination coefficient of each index was 0.308-0.687. The P values of χ2 test were all less than 0.05, which indicated that the degree of coordination of the experts was high. After two rounds of correspondence, Kirkpatrick model-based index system of quality evaluation standard for CWPC pharmacist training was determined. The index system included 4 first-level indexes (participants’ reaction layer, learning gain layer, behavior improvement layer, training outcome layer), 12 second-level indexes (such as training needs, teaching methods, theoretical knowledge, practical skills, job abilities, patient benefits, etc.) and 44 third-level indexes (such as clear training objectives, core system of CWPC, special device operation and evaluation, professional knowledge related to the treatment of cough and wheeze patients, promoting the construction of CWPC, improving patient compliance).CONCLUSIONSThe constructed index system of quality evaluation standard for CWPC pharmacist training has a certain level of authority and scientificity, and provides a scientific theoretical basis for quality evaluation of CWPC pharmacist training.  
      关键词:pharmacist;training quality;evaluation standard;index system;Kirkpatrick model   
      18
      |
      4
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809893 false
      发布时间:2023-11-10
    • ZHENG Yating,KE Yongbo,LIU Yuheng,WANG Yong,ZHENG Zhihua
      Vol. 34, Issue 21, Pages: 2654-2657(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.15
      摘要:OBJECTIVETo analyze the situation of drug use in medical institutions of Guangdong area from 2017 to 2022, and to provide reference for the production, sale and procurement of drugs by government departments, medical insurance departments, pharmaceutical enterprises, drug sales enterprises and hospitals.METHODSUsing the retrospective analysis method, based on original data from Guangdong hospital information network from 2017 to 2022, statistical analysis was conducted on the drug procurement amount of 118 medical institutions that had been online for the past 6 years, as well as the distribution of 14 major categories of drugs among all purchased drugs by online medical institutions, and sales amount of drug production enterprises.RESULTSThe drug procurement amount of 118 medical institutions that had been online in Guangdong area from 2017 to 2022 showed a growth-negative growth-slow growth trend. Among the 14 major categories of drugs, the top 5 drugs in the list of consumption sum were anti-infective drugs, cardiovascular drugs, nervous system drugs, anti-tumor drugs, and digestive system drugs; among the top 200 drugs in terms of procurement amount, three major categories of drugs, namely the anti-infective drugs, anti-tumor drugs and cardiovascular system drugs, occupied the main position. The top 10 drugs in the list of procurement amounts were mainly anti-tumor drugs and cardiovascular system drugs; foreign manufacturers occupied the top 3 places in the list of sales amounts in medical institutions of Guangdong area.CONCLUSIONSIn Guangdong area, the growth of drug procurement amount in medical institutions is gradually slowing down, the usage of anti-infective drugs is still abundant, the prevention and treatment of chronic diseases need great attention, and foreign pharmaceutical companies are in a leading position in the sales amount of medical institutions.  
      关键词:hospital medication;sales amount;drug use trends   
      19
      |
      13
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809880 false
      发布时间:2023-11-10
    • HUANG Huichen,ZHONG Ping,ZHANG Haiyan
      Vol. 34, Issue 21, Pages: 2658-2664(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.16
      摘要:Model-induced drug development (MIDD) is a mathematical and statistical method for constructing, validating and utilizing disease model, drug exposure-response model and pharmaceutical model to promote drug development. With the development of pharmaceutical technology, MIDD is widely used in the field of traditional Chinese medicine and has high practical value. This article summarizes the relevant literature at home and abroad, and finds that MIDD has the advantages of improving the research and development efficiency of traditional Chinese medicine, quickly identifying the applicable population of traditional Chinese medicine, predicting the interaction of drugs, and optimizing the dosage. MIDD has been applied in the studies of effective components of traditional Chinese medicine, quantitative design of prescription, dosage form and preparation process, pilot scale-up, quality and safety, regulatory decision-making and evaluation, etc.  
      关键词:traditional Chinese medicine;application advantage;application advance   
      10
      |
      10
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43810010 false
      发布时间:2023-11-10
    • LI Yunshu,LUO Suxin,HUANG Bi
      Vol. 34, Issue 21, Pages: 2665-2670(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.17
      摘要:Transthyretin cardiac amyloidosis myocardiopathy (ATTR-CM) is an infiltrative cardiomyopathy characterized by the deposition of amyloidogenic material in the myocardial interstitium due to the misfolding of monomers following the dissociation of unstable transthyretin (TTR) tetramers. Previous treatments for ATTR-CM lacked specificity,primarily targeting symptomatic management of heart failure and arrhythmias. In recent years,researchers have developed two major classes of drugs addressing the pathogenesis of ATTR-CM. The first class stabilizes TTR tetramer structure (such as tafamidis and acoramidis),while the second class interferes with TTR synthesis (such as patisiran). Among these,tafamidis has been confirmed as the only currently effective treatment for ATTR-CM,while other drugs are still in clinical trial stages with limited clinical evidence. Concerning the management of comorbidities in ATTR-CM,treatment mainly focuses on common cardiac comorbidities (such as heart failure and arrhythmias). Traditional drugs used to improve heart failure prognosis (such as β-blockers and renin-angiotensin-receptor blocker),have not demonstrated prognosis improvement in ATTR-CM patients and may even lead to adverse reactions. For ATTR-CM patients with concurrent atrial fibrillation,anticoagulation therapy is recommended to prevent thrombus formation,and amiodarone can be used for rhythm control. Despite significant advancements in pharmaceutical treatments for ATTR-CM,the overall prognosis remains poor,necessitating further research into the pathogenesis and target development to enhance the prognosis of ATTR-CM patients.  
      关键词:comorbidities;arrhythmias;heart failure;pharmacotherapy   
      11
      |
      5
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43810058 false
      发布时间:2023-11-10
    • WANG Jinxin,LI Liqun,HUANG Xiaoyan,HUANG Maoguang,LUO Feng,CHEN Yueying,LI Yuling,XIE Sheng,LIU Yuanyuan
      Vol. 34, Issue 21, Pages: 2671-2677(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.18
      摘要:Ulcerative colitis (UC) is a clinical chronic intestinal disease, and the damage of the intestinal epithelial mucus barrier is an important pathological mechanism of UC. Mucin 2 (MUC2) is a major component of the intestinal mucus barrier, and goblet cells are the “main force” of MUC2 secretion, maintaining and renewing the intestinal mucus layer to ensure its integrity. Therefore, repairing the intestinal mucus barrier by promoting the synthesis of MUC2 by goblet cells is an important strategy for the treatment of UC. Traditional Chinese medicine scholars believe that there is an inherent layer of “lipid membrane” or “fat paste” in the intestine, and pathological factors such as moisture and heat lead to the thinning of this structure, which is the fundamental pathogenesis of “diarrhea” and “intestinal dysentery”. It coincides with the damage of intestinal mucus barrier leading to UC in modern medicine. Based on this, this paper summarized the mechanism of Chinese herbal compounds or Chinese herbal active components in regulating intestinal mucus barrier to interfere with UC. It was found that Chinese herbal compounds such as Huanglian jiedu decoction, Shaoyao decoction and Compound Kusen decoction, as well as Chinese herbal active ingredients such as volatile oil of Atractylodes lancea, paeoniflorin and papaya triterpenes could promote the synthesis and secretion function of goblet cells, and achieve the purpose of “thickening intestine”, thus relieving UC symptoms.  
      关键词:ulcerative colitis;mucin 2;goblet cell;intestinal mucus barrier   
      8
      |
      4
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809661 false
      发布时间:2023-11-10
    • CAI Hongye,WU Jin,WANG Xuelian,WANG Guihong,ZHAN Zhilai,ZHENG Guohua,HU Junjie
      Vol. 34, Issue 21, Pages: 2678-2683(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.19
      摘要:Flos Trollii is a traditional Chinese medicinal herb in China. The 2020 edition of the Chinese Pharmacopoeia (part 1) did not include the medicinal herb, its source is not clear, and there is a lack of relevantly systematic and comprehensive research. By consulting ancient Chinese herbal medicines, medical books and related literature, the textual research of Flos Trollii was conducted to verify the name, origin and producing area, so as to provide a reference for the clinical application and resource development of Flos Trollii. Through textual research, it could be seen that the name “Jinlianhua” was used as the correct name in the mainstream origin of the past dynasties, and there were still multiple synonyms such as Hanjinlian, Jinmeicao and so on, most of which originated from its growth environment and appearance. According to the distribution of varieties, it could be inferred that the mainstream origin of Flos Trollii in the Qing Dynasty and before was Trollius chinensis Bge. According to historical records, Flos Trollii were mostly produced in northern regions such as Hebei, Inner Mongolia, Shanxi, etc., which was related to the fact that Flos Trollii liked cloudy, humid and cold environments. Based on the textual research results, the author suggested that the mainstream origin of the past dynasties T. chinensis Bge. should be selected for subsequent collection of Flos Trollii.  
      关键词:name;origin;producing area;herbal textual research   
      8
      |
      7
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809780 false
      发布时间:2023-11-10
    • YUAN Ye,YANG Zhenzhen,YU Bo,SUN Qian,ZHANG Zhiqing
      Vol. 34, Issue 21, Pages: 2684-2688(2023) DOI: 10.6039/j.issn.1001-0408.2023.21.20
      摘要:In recent years, with the increasing understanding of the genetic mechanisms of hypertrophic cardiomyopathy, novel molecular-targeted drugs Mavacamten and Aficamten are two cardiac myosin inhibitors currently approved by the FDA for the treatment of hypertrophic obstructive cardiomyopathy. Both of them have a similar mechanism of action and can selectively bind to different variable sites of cardiac myosin to inhibit cardiac myosin, thus reducing myocardial hypercontractility. Relevant clinical studies have also shown that both drugs can reduce patients’ left ventricular outflow tract pressure gradient, the levels of N-terminal pro-B-type natriuretic peptide and cardiac troponin I as cardiac markers, and improve New York Heart Association (NYHA) cardiac function class. They are safe, have mild adverse reactions, and can be tolerated by patients. Compared to Mavacamten, Aficamten, as a structurally optimized product, has a shorter half-life and fewer drug-drug interactions, which is more conducive to drug-targeted dose titration.  
      关键词:hypertrophic obstructive cardiomyopathy;Mavacamten;Aficamten;molecular-targeted drugs   
      11
      |
      5
      |
      0
      <HTML>
      <L-PDF><WORD><Meta-XML>
      <引用本文> <批量引用> 43809663 false
      发布时间:2023-11-10
    0